There are 717 resources available
443TiP - A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082)
Presenter: Nathalie Gaspar
Session: e-Poster Display Session
7P - Machine learning intratumoral and axillary lymph node magnetic resonance imaging radiomics for predicting axillary lymph node metastasis in patients with early-stage invasive breast cancer (RBC-01 Study)
Presenter: Yujie Tan
Session: e-Poster Display Session
8P - Knowledge, practice and attitudes of physicians in low- and middle-income countries (LMIC) on fertility and pregnancy-related issues in young breast cancer patients
Presenter: Shah Zeb Khan
Session: e-Poster Display Session
67TiP - HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer
Presenter: Norikazu Masuda
Session: e-Poster Display Session
68TiP - KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC
Presenter: Shigehira Saji
Session: e-Poster Display Session
Introduction
Presenter: Byoung Cho
Session: Boehringer Ingelheim - Treatment Considerations for Advanced NSCLC: Now and in the Future
Resources:
Webcast
Navigating first-line treatment decisions for EGFRM+ NSCLC: Extrapolating from Asian clinical trial experience
Presenter: John Wen-Cheng Chang
Session: Boehringer Ingelheim - Treatment Considerations for Advanced NSCLC: Now and in the Future
Resources:
Webcast
Tackling Uncommon EGFR mutations: Efficacy of EGFR TKIs in NSCLC
Presenter: Hiroshi Tanaka
Session: Boehringer Ingelheim - Treatment Considerations for Advanced NSCLC: Now and in the Future
Resources:
Webcast
KRAS-mutant NSCLC treatment advances on the horizon
Presenter: Byoung Cho
Session: Boehringer Ingelheim - Treatment Considerations for Advanced NSCLC: Now and in the Future
Resources:
Webcast
Closing
Presenter: Byoung Cho
Session: Boehringer Ingelheim - Treatment Considerations for Advanced NSCLC: Now and in the Future
Resources:
Webcast